anti jak2 antibody  (Servicebio Inc)

Journal: Molecular Medicine Reports

Article Title: Long non-coding RNA NKILA regulates the JAK2/STAT3 pathway to exacerbate TGF-β1-mediated renal fibrosis

doi: 10.3892/mmr.2026.13839

Figure Lengend Snippet: JKA2/STAT3 pathway protein detection in HK-2 cells transfected with LncRNA NKILA overexpression virus (A) Representative western blotting bands and (B) semi-quantification of results of protein expression of phosphorylated JAK2 and STAT3 (n=3). (C) RT-qPCR statistical results (n=3). ## P<0.01 and # P<0.05 compared with the normal group. ns, not significant; p-, phosphorylated; OE, overexpression; NC, negative control; JAK, Janus kinase; RT-qPCR, reverse transcription quantitative PCR.

Article Snippet: After blocking with 5% non-fat milk for 2 h at room temperature, membranes were incubated overnight at 4°C with primary antibodies against fibronectin (FN; 1:1,000; cat. no. ab45688; Abcam), collagen I (Col1; 1:1,000; cat. no. ab138492; Abcam), vimentin (Vim; 1:1,000; cat. no. 10366-1-AP; Proteintech Group, Inc.), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. 14395-1-AP; Proteintech Group, Inc.), JAK2 (1:1,000; cat. no. 17670-1-AP; Proteintech Group, Inc.), STAT3 (1:1,000; cat. no. 10253-2-AP; Proteintech Group, Inc.), phosphorylated (p)-JAK2 (1:500; cat. no. ab32101; Abcam), p-STAT3 (1:500; cat. no. ab76315; Abcam) and GAPDH (1:5,000; cat. no. 10494-1-AP; Proteintech Group, Inc.).

Techniques: Transfection, Over Expression, Virus, Western Blot, Expressing, Quantitative RT-PCR, Negative Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Molecular Medicine Reports

Article Title: Long non-coding RNA NKILA regulates the JAK2/STAT3 pathway to exacerbate TGF-β1-mediated renal fibrosis

doi: 10.3892/mmr.2026.13839

Figure Lengend Snippet: JAK2/STAT3 signaling pathway-associated proteins in HK-2 cells transfected with LncRNA NKILA knockdown lentivirus (A) Representative western blotting bands and (B) semi-quantification of JAK2/STAT3 pathway protein expression (n=3). (C) Statistical analysis results of reverse transcription-quantitative PCR for channel indicators. ## P<0.01 compared with the normal group (n=3), **P<0.01 and *P<0.05 compared with the control + KD-NC group. JAK, Janus kinase; KD, knockdown; NC, negative control; p-, phosphorylated.

Article Snippet: After blocking with 5% non-fat milk for 2 h at room temperature, membranes were incubated overnight at 4°C with primary antibodies against fibronectin (FN; 1:1,000; cat. no. ab45688; Abcam), collagen I (Col1; 1:1,000; cat. no. ab138492; Abcam), vimentin (Vim; 1:1,000; cat. no. 10366-1-AP; Proteintech Group, Inc.), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. 14395-1-AP; Proteintech Group, Inc.), JAK2 (1:1,000; cat. no. 17670-1-AP; Proteintech Group, Inc.), STAT3 (1:1,000; cat. no. 10253-2-AP; Proteintech Group, Inc.), phosphorylated (p)-JAK2 (1:500; cat. no. ab32101; Abcam), p-STAT3 (1:500; cat. no. ab76315; Abcam) and GAPDH (1:5,000; cat. no. 10494-1-AP; Proteintech Group, Inc.).

Techniques: Transfection, Knockdown, Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Control, Negative Control

Journal: Molecular Medicine Reports

Article Title: Long non-coding RNA NKILA regulates the JAK2/STAT3 pathway to exacerbate TGF-β1-mediated renal fibrosis

doi: 10.3892/mmr.2026.13839

Figure Lengend Snippet: JAK2/STAT3 pathway protein detection in the recovery experiment of HK-2 cells treated with AG490. (A) Representative western blotting bands and (B) semi-quantification of JAK2/STAT3 pathway protein expression (n=3). (C) Reverse transcription-quantitative PCR for channel indicators (n=3). ## P<0.01 compared with the normal group, **P<0.01 and *P<0.05 compared with control + DMSO group and △△ P<0.01 compared with OE-NKILA group. OE, overexpression; p-, phosphorylated; JAK, Janus kinase; ns, not significant.

Article Snippet: After blocking with 5% non-fat milk for 2 h at room temperature, membranes were incubated overnight at 4°C with primary antibodies against fibronectin (FN; 1:1,000; cat. no. ab45688; Abcam), collagen I (Col1; 1:1,000; cat. no. ab138492; Abcam), vimentin (Vim; 1:1,000; cat. no. 10366-1-AP; Proteintech Group, Inc.), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. 14395-1-AP; Proteintech Group, Inc.), JAK2 (1:1,000; cat. no. 17670-1-AP; Proteintech Group, Inc.), STAT3 (1:1,000; cat. no. 10253-2-AP; Proteintech Group, Inc.), phosphorylated (p)-JAK2 (1:500; cat. no. ab32101; Abcam), p-STAT3 (1:500; cat. no. ab76315; Abcam) and GAPDH (1:5,000; cat. no. 10494-1-AP; Proteintech Group, Inc.).

Techniques: Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Control, Over Expression

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: Effect of BG on JAK2/STAT3/HMGB1 signaling pathway in LPS-induced BV2. (A) Quantification of the p-JAK2/JAK2 in LPS-induced BV2 (n = 3). (B) Quantification of the p-STAT3/STAT3 in LPS-induced BV2 (n = 3). (C) Quantification of the HMGB1 in LPS-induced BV2 (n = 3). (D) Quantification of the HMGB1 in the cytoplasm in LPS-induced BV2 (n = 3). (E) Quantification of the HMGB1 in the nucleus in LPS-induced BV2 (n = 3). Compared with the control group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with the BG-10 μg/mL group, △ p < 0.05, △△ p < 0.01, △△△ p < 0.001.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: Effect of BG on JAK2/STAT3/HMGB1 signalling pathway in brain tissue of MCAO rats. (A–C) Expression of HMGB1 in brain, lung tissues and serum (n = 6). (D) Quantification of the p-JAK2/JAK2 in brains (n = 3). (E) Quantification of the p-STAT3/STAT3 in brains (n = 3). (F) Quantification of the HMGB1 in brains (n = 3). (G) Quantification of the HMGB1 in the cytoplasm in brains (n = 3). (H) Quantification of the HMGB1 in the nucleus in brains (n = 3). (I) Immunofluorescence assay of HMGB1 in brain tissues. Compared with the sham group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with the BG-25 mg/kg group, △ p < 0.05, △△ p < 0.01.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Expressing, Immunofluorescence

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: In LPS-induced BV2, BG reduces JAK2 activation and blocks the JAK2-STAT3-HMGB1 pathway, thereby reducing the inflammatory response. (A) Quantification of the p-JAK2/JAK2 in BV2 (n = 3). (B) Quantification of the p-STAT3/STAT3 in BV2 (n = 3). (C) Quantification of the HMGB1 in BV2 (n = 3). (D) Immunofluorescence assay of HMGB1. Compared with the control group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05; compared with the BG-50 μg/mL group, △ p < 0.05, △△ p < 0.01; compared with the CA1 group, ○ p < 0.05, ○○ p < 0.01.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Activation Assay, Immunofluorescence, Control

Journal: Journal of Hepatocellular Carcinoma

Article Title: Pleione bulbocodioides Polysaccharides Reprogram Tumor-Associated Macrophages via JAK2/STAT3 Inhibition to Suppress Hepatocellular Carcinoma

doi: 10.2147/JHC.S578276

Figure Lengend Snippet: Effects of PBPs on modulating macrophage polarization and the expression of genes related to the JAK2/STAT3 pathway in tumors. ( A and B ) M2 markers (Arg-1, and CD206); ( C and D ) M1 markers (CD86, and iNOS); ( E and F ) JAK2 and STAT3 transcripts. Data are presented as mean ± SD (n = 3).

Article Snippet: Primary antibodies against JAK2 (cat. no. AF6022), phospho-JAK2 (cat. no. AF3024), STAT3 (cat. no. AF6294), phospho-STAT3 (cat. no. AF3293), BCL-2 (cat. no. AF6139), and β-Actin (cat. no. AF7018) (Affinity Biosciences, Cincinnati, OH, USA).

Techniques: Expressing

Journal: Journal of Hepatocellular Carcinoma

Article Title: Pleione bulbocodioides Polysaccharides Reprogram Tumor-Associated Macrophages via JAK2/STAT3 Inhibition to Suppress Hepatocellular Carcinoma

doi: 10.2147/JHC.S578276

Figure Lengend Snippet: Effects of PBPs on regulating protein expression related to JAK2/STAT3 signaling, apoptosis, and angiogenesis in tumors. ( A ) Representative Western blot images; ( B ) p-JAK2/JAK2; ( C ) p-STAT3/STAT3; ( D ) BCL-2; ( E ) BAX; ( F ) VEGF. Data are presented as mean ± SD (n = 3).

Article Snippet: Primary antibodies against JAK2 (cat. no. AF6022), phospho-JAK2 (cat. no. AF3024), STAT3 (cat. no. AF6294), phospho-STAT3 (cat. no. AF3293), BCL-2 (cat. no. AF6139), and β-Actin (cat. no. AF7018) (Affinity Biosciences, Cincinnati, OH, USA).

Techniques: Expressing, Western Blot